Successful management of prostate cancer with bulky pelvic lymph node metastases after rapid development of castration-resistant prostate cancer: a case report with review of the literature.
Case report
castration-resistant
chemotherapy
prostate cancer
radiotherapy
Journal
Translational andrology and urology
ISSN: 2223-4691
Titre abrégé: Transl Androl Urol
Pays: China
ID NLM: 101581119
Informations de publication
Date de publication:
Jun 2020
Jun 2020
Historique:
entrez:
18
7
2020
pubmed:
18
7
2020
medline:
18
7
2020
Statut:
ppublish
Résumé
The rapid development of castration-resistant prostate cancer (CRPC) is a poor prognostic sign for loco-regionally advanced prostate cancer. Non-metastatic CRPC (nmCRPC) with bulky regional lymph node metastases is extremely rare and difficult to treat clinically without reported case. We present a case of a 72-year-old man with locally advanced prostate cancer with bulky lymph node metastases (53 mm × 77 mm × 67 mm), developing nmCRPC after 9-month ADT treatment. Immunohistochemistry (IHC) tests found partially positive MUC1 and negative BRCA1 expression in the initial biopsy specimens. Next-generation sequence analysis on the blood specimen after CRPC predicted a good tolerance to docetaxel. According to the multidisciplinary team recommendations, he was administrated docetaxel 75 mg/m
Identifiants
pubmed: 32676427
doi: 10.21037/tau-20-725
pii: tau-09-03-1428
pmc: PMC7354291
doi:
Types de publication
Case Reports
Langues
eng
Pagination
1428-1436Informations de copyright
2020 Translational Andrology and Urology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tau-20-725). The authors have no conflicts of interest to declare.
Références
Clin Oncol (R Coll Radiol). 2015 Jan;27(1):16-21
pubmed: 25445554
Clin Cancer Res. 2009 May 15;15(10):3251-5
pubmed: 19447877
Eur J Cancer. 2012 Jan;48(2):209-17
pubmed: 22119204
Eur J Cancer. 2015 Sep;51(14):1946-52
pubmed: 26208462
J Clin Epidemiol. 2017 Sep;89:218-235
pubmed: 28529185
Anticancer Res. 2004 Sep-Oct;24(5B):3141-5
pubmed: 15510602
BJU Int. 2009 Nov;104(10):1462-6
pubmed: 19522869
Prostate. 2018 May;78(7):498-505
pubmed: 29473179
Zhonghua Zhong Liu Za Zhi. 2019 Jan 23;41(1):19-28
pubmed: 30678413
Int J Radiat Oncol Biol Phys. 2009 Jul 1;74(3):759-65
pubmed: 19327908
World J Urol. 2016 Sep;34(9):1239-45
pubmed: 26612676
Prostate. 2018 Jul;78(10):766-772
pubmed: 29635810
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):372-9
pubmed: 15145150
Eur Urol. 2016 Oct;70(4):599-608
pubmed: 27117751
J Clin Oncol. 2019 May 10;37(14):1159-1168
pubmed: 30860948
J Clin Oncol. 2016 May 10;34(14):1652-9
pubmed: 26951312
Int J Cancer. 2019 Dec 1;145(11):2974-2985
pubmed: 30968962
Prostate Cancer Prostatic Dis. 2016 Sep;19(3):242-7
pubmed: 27165976
JAMA Oncol. 2016 Mar;2(3):348-57
pubmed: 26606329
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593